Literature DB >> 25465521

Molecular characterisation of extensively drug-resistant Mycobacterium tuberculosis isolates in China.

Li-li Zhao1, Qing Sun2, Chun-yan Zeng3, Yan Chen2, Bing Zhao4, Hai-can Liu1, Qiang Xia5, Xiu-qin Zhao1, Wei-wei Jiao6, Gui-lian Li1, Kang-lin Wan7.   

Abstract

The emergence of extensively drug-resistant tuberculosis (XDR-TB) in China is a great threat to TB control. To determine the molecular characterisation of XDR-TB isolates from China and the correlations between specific drug resistance-associated mutations and different genotype strains, 58 XDR-TB isolates were sequenced in eight drug loci, including katG, inhA, oxyR-ahpC intergenic region, rpoB, eis, rrs, gyrA and gyrB, and were genotyped using spoligotyping and analysis of the noise transfer function region. Compared with the phenotypic data, the sensitivities and specificities for DNA sequencing were 87.9% and 100.0% for isoniazid (INH), 91.4% and 98.3% for rifampicin (RIF), 60.4% and 100.0% for kanamycin (KAN) and 81.0% and 100.0% for ofloxacin (OFX), respectively. A combination of eight drug loci predicted XDR-TB phenotypes with 53.4% sensitivity (31/58 isolates) and 100.0% specificity. The most frequent mutations among these XDR-TB isolates were katG315 and inhA-15 (for INH), 531, 526 and 516 in rpoB (for RIF), rrs1401 and eis-10 (for KAN) and 94, 90 and 91 in gyrA (for OFX). Also, among these XDR-TB isolates, 44 (75.9%) were identified as Beijing genotype strain, of which 31 (70.5%) belonged to the modern Beijing sublineage. inhA-8, rpoB526 and rpoB531 mutations demonstrated significant statistical associations with ancient and modern Beijing family sublineage (P<0.05). However, Beijing and non-Beijing genotypes showed no association with specific resistance-conferring mutations. These results will be helpful in designing new molecular biology-based techniques to diagnose XDR-TB in China.
Copyright © 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Extensively drug-resistant tuberculosis; Genotype; Molecular characterisation; Resistance-conferring mutations

Mesh:

Substances:

Year:  2014        PMID: 25465521     DOI: 10.1016/j.ijantimicag.2014.09.018

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Molecular characteristics of ofloxacin mono-resistant Mycobacterium tuberculosis isolates from new and previously treated tuberculosis patients.

Authors:  Zhirui Wang; Tong Xie; Cheng Mu; Chunhua Wang; Hanfang Ju; Hui Zhao; Rui Sun
Journal:  J Clin Lab Anal       Date:  2017-03-20       Impact factor: 2.352

2.  Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.

Authors:  Xia Yu; Guirong Wang; Suting Chen; Guomei Wei; Yuanyuan Shang; Lingling Dong; Thomas Schön; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Claudio U Köser; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

3.  Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China.

Authors:  Qiao Liu; Dandan Yang; Beibei Qiu; Leonardo Martinez; Ye Ji; Huan Song; Zhongqi Li; Jianming Wang
Journal:  PLoS Negl Trop Dis       Date:  2021-01-20

4.  A Chip for Detecting Tuberculosis Drug Resistance Based on Polymerase Chain Reaction (PCR)-Magnetic Bead Molecule Platform.

Authors:  Jingtong Lyu; Wenjie Wu; Peng Cheng; Xun Liu; Fei Luo; Zehua Zhang; Kanglai Tang; Jianzhong Xu
Journal:  Front Microbiol       Date:  2018-09-07       Impact factor: 5.640

5.  Prevalence, risk and genetic characteristics of drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China.

Authors:  Li-Li Zhao; Ming-Xiang Huang; Tong-Yang Xiao; Hai-Can Liu; Ma-Chao Li; Xiu-Qin Zhao; Zhi-Guang Liu; Yi Jiang; Kang-Lin Wan
Journal:  Infect Drug Resist       Date:  2019-08-07       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.